Portal de Periódicos da CAPES

Artigo Acesso aberto Produção Nacional Revisado por pares

BIBTEX RIS

Soluble epoxide hydrolase inhibitor, TPPU, increases regulatory T cells pathway in an arthritis model

2020; Wiley; Volume: 34; Issue: 7 Linguagem: Inglês

10.1096/fj.202000415r

1530-6860

Carlos Antônio Trindade‐da‐Silva, Juliana Trindade Clemente‐Napimoga, Henrique Ballassini Abdalla, Sergio Marcolino Rosa, Carlos Ueira‐Vieira, Christophe Morisseau, Waldiceu A. Verri, Victor Ângelo Martins Montalli, Bruce D. Hammock, Marcelo Henrique Napimoga,

Peroxisome Proliferator-Activated Receptors

Epoxyeicosatrienoic acids (EET) and related epoxy fatty acids (EpFA) are endogenous anti-inflammatory compounds, which are converted by the soluble epoxide hydrolase (sEH) to dihydroxylethersatrienoic acids (DHETs) with lessened biological effects. Inhibition of sEH is used as a strategy to increase EET levels leading to lower inflammation. Rheumatoid arthritis is a chronic autoimmune disease that leads to destruction of joint tissues. This pathogenesis involves a complex interplay between the immune system, and environmental factors. Here, we investigate the effects of inhibiting sEH with 1-trifluoromethoxyphenyl-3-(1-propionylpiperidin-4-yl) urea (TPPU) on a collagen-induced arthritis model. The treatment with TPPU ameliorates hyperalgesia, edema, and decreases the expression of important pro-inflammatory cytokines of Th1 and Th17 profiles, while increasing Treg cells. Considering the challenges to control RA, this study provides robust data supporting that inhibition of the sEH is a promising target to treat arthritis.